Likewise, LncRNA SOX2‐OT promotes a functional modulation of the EGFR‐AKT‐ERK expression‐activation, promoting resistance to cisplatin/EGFR‐TKI‐erlotinib therapy, determining poorer overall survival of lung cancer patients. This evidence concerns the gene AKT1 and lung carcinoma.